Correlation Between Merus BV and Kalvista Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Merus BV and Kalvista Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Merus BV and Kalvista Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Merus BV and Kalvista Pharmaceuticals, you can compare the effects of market volatilities on Merus BV and Kalvista Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Merus BV with a short position of Kalvista Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Merus BV and Kalvista Pharmaceuticals.
Diversification Opportunities for Merus BV and Kalvista Pharmaceuticals
0.7 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Merus and Kalvista is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Merus BV and Kalvista Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kalvista Pharmaceuticals and Merus BV is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Merus BV are associated (or correlated) with Kalvista Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kalvista Pharmaceuticals has no effect on the direction of Merus BV i.e., Merus BV and Kalvista Pharmaceuticals go up and down completely randomly.
Pair Corralation between Merus BV and Kalvista Pharmaceuticals
Given the investment horizon of 90 days Merus BV is expected to generate 0.44 times more return on investment than Kalvista Pharmaceuticals. However, Merus BV is 2.29 times less risky than Kalvista Pharmaceuticals. It trades about -0.09 of its potential returns per unit of risk. Kalvista Pharmaceuticals is currently generating about -0.06 per unit of risk. If you would invest 5,177 in Merus BV on August 28, 2024 and sell it today you would lose (638.00) from holding Merus BV or give up 12.32% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Merus BV vs. Kalvista Pharmaceuticals
Performance |
| Timeline |
| Merus BV |
| Kalvista Pharmaceuticals |
Merus BV and Kalvista Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Merus BV and Kalvista Pharmaceuticals
The main advantage of trading using opposite Merus BV and Kalvista Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Merus BV position performs unexpectedly, Kalvista Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kalvista Pharmaceuticals will offset losses from the drop in Kalvista Pharmaceuticals' long position.| Merus BV vs. Anebulo Pharmaceuticals | Merus BV vs. Adagene | Merus BV vs. Acrivon Therapeutics, Common | Merus BV vs. AnaptysBio |
| Kalvista Pharmaceuticals vs. Crinetics Pharmaceuticals | Kalvista Pharmaceuticals vs. Kura Oncology | Kalvista Pharmaceuticals vs. Viridian Therapeutics | Kalvista Pharmaceuticals vs. Replimune Group |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Complementary Tools
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |